Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
- 30 April 1995
- journal article
- clinical trial
- Published by Elsevier in American Journal Of Medicine
- Vol. 98 (4), 412-414
- https://doi.org/10.1016/s0002-9343(99)80323-4
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate CancerJNCI Journal of the National Cancer Institute, 1994
- Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination TherapyJournal of Urology, 1993
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal SyndromeJournal of Urology, 1993
- Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapyCancer, 1993
- Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized TrialJournal of Urology, 1993
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4'–Nitro–3'–Trifluoromethylisobutyranilide)1Endocrinology, 1972
- STUDIES ON PROSTATIC CANCERArchives of Surgery, 1941